SplashBIO Launches as an Independent Platform Company for Biomarker-Driven Clinical Trial Enrollment

Contributed by: GlobeNewswire

Tags

biotech

More Like This

Dementia Mission Competition Selects Four Companies For Innovative Alzheimer’s Biomarker Study

Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzheimer’s and Related Disorders – ICON Survey

PR Newswire associated0

Sysmex launches HISCL™ platform, enabling faster, scalable Alzheimer's blood testing

PR Newswire associated0

Alamar Biosciences, Alzheimer's Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer's Disease.

SISCAPA and Biognosys Announce Strategic Collaboration to Deliver End-to-End High-Sensitivity Targeted Protein Quantification Solutions

Biognosys Presents Major Innovations Across the Spectrum of Proteomics Research Applications at the HUPO World Congress

PR Newswire associated0

FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025: ALZHEIMER'S ASSOCIATION RELEASES ITS FIRST CLINICAL PRACTICE GUIDELINE FOR BLOOD-BASED BIOMARKER TESTS

PR Newswire associated0

AsymBio Establishes Integrated Technology Platforms Spanning the Full Biopharmaceutical Development Lifecycle